Condition: Acute Lymphoblastic Leukemia, in Relapse · Acute Lymphoblastic Leukemia With Failed Remission · B-cell Lymphoma Refractory · Sponsor: Rong Tao
This study examines the safety, tolerability and preliminary efficacy of anti-CD19 /CD22 CAR T cells (KQ-2002)manufactured on-site in adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin lymphoma.
This description comes directly from the study's public registry record.
Weijing Zhang · 021-64175590 · JJYIN555@163.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Nanchang University; | Nanchang, Jiangxi, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06445803